CTBP2 and benign prostatic hyperplasia: Similarly, treatment with antiandrogens had a minimal impact on the expression of any of the transcripts studied; with the exception of CTBP2(1) and CTBP2(4) transcripts, which showed a trend towards lower expression in samples from prostate cancer patients treated with hormone therapy, although this result was not statistically significant and no correlations of the expression of either transcript with hormone therapy was noted in the BPH cohort.